ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ensifentrine

Also written as “Ensifentrine”, “RPL554” and “Ensifentrine 3 mg”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis · Asthma, led by 2 companies.

Drug pageEnsifentrine: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 19, 202017 company-led studies, 2 open or runningAcquisition: Merck acquired Verona Pharma, Oct 2025Next primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only152 open or runningphase 3since Aug 19, 2020Nov 30, 2014Mar 1, 2027phase 2 · NCT05270525
Nuance Pharma (shanghai)20 open or runningphase 3since Feb 14, 2023Feb 14, 2023none ahead
  • Named in Merck’s own pipeline as ensifentrine (+) glycopyrrolate (MK-5884A), phase 2, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Laboratory Corporation of America and Iqvia Pty.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseNuance Pharma licensed it from Verona Pharma, for Greater China (mainland China, Taiwan, Hong Kong and Macau).Agreed Jun 9, 2021 · Source: Verona Pharma (8-K), Jun 11, 2021
  • AcquisitionMerck acquired Verona Pharma, and with it ensifentrine (Ohtuvayre).Completed Oct 7, 2025 · Source: Merck, Oct 7, 2025

History and studies of Nuance Pharma (shanghai) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named ensifentrineINNProposed as its International Nonproprietary Name in WHO's List 119 · before, RPL554
  2. Jun 9, 2021Nuance Pharma licensed it from Verona PharmaLicenseGreater China (mainland China, Taiwan, Hong Kong and Macau) · agreed · Verona Pharma (8-K)
  3. Feb 14, 2023First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05758428 · 28 enrolled · China
  4. Feb 14, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT05743075 · 526 enrolled · China
  5. Oct 7, 2025Merck acquired Verona PharmaAcquisitionWith it ensifentrine (Ohtuvayre) · completed · Merck

TargetBeta

“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-…”NCIt, read by Claude
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), ”NCIt, by rule
“Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor”ChEMBL 37, by rule

Studies

All 2 Nuance Pharma (shanghai) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05758428Pulmonary Disease, Chronic Obstructive · China1CompletedApr 18, 202328
NCT05743075Pulmonary Disease, Chronic Obstructive · China3CompletedDec 6, 2024526

How it is read

Names in the registry

  • “Ensifentrine”, 7 entries
  • “RPL554”, 4 entries
  • “Ensifentrine 3 mg”, 2 entries
  • “Ensifentrine 1.5 mg”, 1 entry
  • “Ensifentrine 3 mg (marketed formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.